Elanco Animal Health (NYSE:ELAN) Releases Q1 Earnings Guidance

Elanco Animal Health (NYSE:ELAN) issued an update on its first quarter earnings guidance on Tuesday morning. The company provided earnings per share guidance of $0.29-$0.34 for the period, compared to the consensus earnings per share estimate of $0.30. The company issued revenue guidance of $1.155-$1.180 billion, compared to the consensus revenue estimate of $1.21 billion. Elanco Animal Health also updated its FY 2025 guidance to 0.800-0.860 EPS.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. Leerink Partners began coverage on Elanco Animal Health in a report on Monday, December 2nd. They issued a “market perform” rating and a $14.00 target price for the company. Leerink Partnrs upgraded Elanco Animal Health to a “hold” rating in a report on Monday, December 2nd. Stifel Nicolaus lowered their target price on shares of Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating on the stock in a research note on Friday, February 21st. Barclays reduced their price target on shares of Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating for the company in a research note on Wednesday. Finally, UBS Group initiated coverage on shares of Elanco Animal Health in a research report on Monday, December 9th. They set a “buy” rating and a $18.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $15.86.

Elanco Animal Health Stock Performance

Shares of NYSE:ELAN traded up $0.64 during trading on Wednesday, hitting $11.34. The company’s stock had a trading volume of 653,934 shares, compared to its average volume of 4,788,184. Elanco Animal Health has a 12 month low of $10.20 and a 12 month high of $18.80. The company has a 50-day moving average of $11.75 and a 200-day moving average of $13.07. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The firm has a market cap of $5.61 billion, a price-to-earnings ratio of 28.34, a P/E/G ratio of 2.50 and a beta of 1.42.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01). Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.01 billion. During the same quarter in the previous year, the company posted $0.08 EPS. The company’s quarterly revenue was down 1.4% on a year-over-year basis. On average, sell-side analysts expect that Elanco Animal Health will post 0.91 earnings per share for the current year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.